{"id":976275,"date":"2026-06-26T17:22:11","date_gmt":"2026-06-26T21:22:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/"},"modified":"2026-06-26T17:22:11","modified_gmt":"2026-06-26T21:22:11","slug":"matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/","title":{"rendered":"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance"},"content":{"rendered":"
\n

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (the \u201cCompany\u201d) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the \u201cNotice\u201d) from the NYSE American LLC (the \u201cNYSE American\u201d) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) requiring a company to have stockholders\u2019 equity of at least $4.0 million if it has reported losses from continuing operations and\/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders\u2019 equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders\u2019 equity of at least $6.0 million if it has reported losses from continuing operations and\/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders\u2019 equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.<\/p>\n

On May 4, 2026, the Company submitted a plan (the \u201cPlan\u201d) to the NYSE American advising of actions it has taken or will take to regain compliance with the continued listing standards. The Notice indicated that the NYSE American staff had determined to accept the Plan and grant the Company a plan period through October 2, 2027 (the \u201cPlan Period,\u201d and such date, the \u201cPlan Period Deadline\u201d). Accordingly, the Company is able to continue its listing during the Plan Period and will be subject to periodic reviews, including quarterly monitoring, for compliance with the Plan until it has regained compliance. However, there can be no assurance that the Company will be able to achieve compliance with such standards within the Plan Period. If the Company is not in compliance with the continued listing standards by the Plan Period Deadline, or if the Company does not make progress consistent with the Plan during the Plan Period, then NYSE American staff may initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.<\/p>\n

The Notice has no immediate impact on the listing of the Company\u2019s shares of common stock, which will continue to be listed and traded on the NYSE American, subject to the Company\u2019s compliance with the other listing requirements of the NYSE American. The Notice does not affect the Company\u2019s ongoing business operations or its reporting requirements with the Securities and Exchange Commission.
\u00a0\u00a0
About Matinas BioPharma<\/strong><\/p>\n

Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.<\/p>\n

\n About MAT2203<\/strong>\n <\/p>\n

Matinas BioPharma\u2019s MAT2203 is a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with several significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.<\/p>\n

For more information, please visit www.matinasbiopharma.com<\/a>.\u00a0<\/p>\n

\n Forward-Looking Statements <\/strong>\n <\/p>\n

This release contains \u201cforward-looking\u201d statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this release are forward-looking statements. Forward-looking statements contained in this release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including with respect to the Company\u2019s plans related to regaining compliance with the NYSE American\u2019s continued listing standards. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the risk disclosures in the Annual Report on Form 10-K of the Company for the year ended December 31, 2025 and in other filings made with the Securities and Exchange Commission by the Company. All such forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Investor Contact\r\n\r\nJerome D. Jabbour\r\nChief Executive Officer\r\n(908) 484-8805\r\noperations@matinasbiopharma.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (the \u201cCompany\u201d) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the \u201cNotice\u201d) from the NYSE American LLC (the \u201cNYSE American\u201d) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) requiring a company to have stockholders\u2019 equity of at least $4.0 million if it has reported losses from continuing operations and\/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders\u2019 equity of $3.02 million and has had losses in the most recent … <\/p>\n
Continue reading “Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-976275","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (the \u201cCompany\u201d) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the \u201cNotice\u201d) from the NYSE American LLC (the \u201cNYSE American\u201d) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) requiring a company to have stockholders\u2019 equity of at least $4.0 million if it has reported losses from continuing operations and\/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders\u2019 equity of $3.02 million and has had losses in the most recent … Continue reading "Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T21:22:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance\",\"datePublished\":\"2026-06-26T21:22:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/\"},\"wordCount\":945,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/\",\"name\":\"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=\",\"datePublished\":\"2026-06-26T21:22:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/","og_locale":"en_US","og_type":"article","og_title":"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance - Market Newsdesk","og_description":"BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (the \u201cCompany\u201d) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the \u201cNotice\u201d) from the NYSE American LLC (the \u201cNYSE American\u201d) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) requiring a company to have stockholders\u2019 equity of at least $4.0 million if it has reported losses from continuing operations and\/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders\u2019 equity of $3.02 million and has had losses in the most recent … Continue reading \"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-26T21:22:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance","datePublished":"2026-06-26T21:22:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/"},"wordCount":945,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/","name":"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=","datePublished":"2026-06-26T21:22:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-and-acceptance-of-plan-to-regain-compliance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=976275"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976275\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=976275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=976275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=976275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}